CL2015003023A1 - Liberacion sostenida de bimatoprost, analogos de bimatoprost, prostamidas y prostaglandinas para la reduccion de grasas. - Google Patents
Liberacion sostenida de bimatoprost, analogos de bimatoprost, prostamidas y prostaglandinas para la reduccion de grasas.Info
- Publication number
- CL2015003023A1 CL2015003023A1 CL2015003023A CL2015003023A CL2015003023A1 CL 2015003023 A1 CL2015003023 A1 CL 2015003023A1 CL 2015003023 A CL2015003023 A CL 2015003023A CL 2015003023 A CL2015003023 A CL 2015003023A CL 2015003023 A1 CL2015003023 A1 CL 2015003023A1
- Authority
- CL
- Chile
- Prior art keywords
- bimatoprost
- sustained release
- prostamides
- prostaglandins
- analogs
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/559—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing hetero atoms other than oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts or implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Ophthalmology & Optometry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Child & Adolescent Psychology (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Materials For Medical Uses (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361811682P | 2013-04-12 | 2013-04-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2015003023A1 true CL2015003023A1 (es) | 2016-06-10 |
Family
ID=51686960
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2015003023A CL2015003023A1 (es) | 2013-04-12 | 2015-10-09 | Liberacion sostenida de bimatoprost, analogos de bimatoprost, prostamidas y prostaglandinas para la reduccion de grasas. |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US20140308354A1 (enExample) |
| EP (2) | EP2983663B1 (enExample) |
| JP (1) | JP2016520561A (enExample) |
| KR (1) | KR20150141972A (enExample) |
| CN (2) | CN110840899A (enExample) |
| AU (2) | AU2014250937A1 (enExample) |
| BR (1) | BR112015025915A8 (enExample) |
| CA (1) | CA2908731A1 (enExample) |
| CL (1) | CL2015003023A1 (enExample) |
| DK (1) | DK2983663T3 (enExample) |
| ES (1) | ES2785382T3 (enExample) |
| IL (1) | IL242006B (enExample) |
| MX (1) | MX381097B (enExample) |
| MY (1) | MY187802A (enExample) |
| RU (1) | RU2015143859A (enExample) |
| SG (2) | SG10201701938PA (enExample) |
| WO (1) | WO2014169075A1 (enExample) |
| ZA (1) | ZA201507217B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102159427B1 (ko) * | 2015-04-30 | 2020-09-24 | 알러간, 인코포레이티드 | 지방 감소를 위한 미용적 방법 및 치료적 용도 |
| US11452703B2 (en) * | 2020-05-21 | 2022-09-27 | Peregrine Ophthalmic PTE LTD. | Methods and compositions for reducing adipocyte numbers |
| JP7879845B2 (ja) * | 2020-07-21 | 2026-06-24 | アラーガン、インコーポレイテッド | プロスタミドが高充填された眼内インプラント |
| EP4698184A1 (en) * | 2023-04-18 | 2026-02-25 | Welfare Concepts Limited | Composition and method for inducing luteolysis |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2218424A (en) * | 1931-05-07 | 1940-10-15 | Teleregister Corp | Transmitter and code translator |
| US4525359A (en) * | 1982-12-10 | 1985-06-25 | Greenway Frank L Iii | Treatment for selective weight control |
| US6124344A (en) * | 1993-12-28 | 2000-09-26 | Allergan Sales, Inc. | Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents |
| DE69613693T2 (de) * | 1995-05-18 | 2002-05-16 | Allergan Sales, Inc. | 2-heteroarylalkenylderivate der cyclopentano-heptan(heptaen)säure als therapeutisches mittel zur behandlung des erhöhten augeninnendruckes |
| ES2379652T3 (es) | 2002-10-23 | 2012-04-30 | Sucampo Ag | Compuestos de prostaglandina para el tratamiento de obesidad |
| CA2508303C (en) * | 2002-12-04 | 2012-10-23 | Santen Pharmaceutical Co., Ltd. | Drug delivery system using subconjunctival depot |
| WO2005063205A2 (en) * | 2003-12-22 | 2005-07-14 | Aventis Pharmaceuticals Inc. | Injectable phosphatidylcholine preparations |
| US20080038316A1 (en) | 2004-10-01 | 2008-02-14 | Wong Vernon G | Conveniently implantable sustained release drug compositions |
| WO2007111806A2 (en) * | 2006-03-23 | 2007-10-04 | Massachusetts Eye And Ear Infirmary | Cyclopentane heptanoic acid compounds for reducing body fat |
| AU2007313077B2 (en) * | 2006-10-17 | 2011-06-02 | Neothetics, Inc. | Methods, compositions, and formulations for the treatment of thyroid eye disease |
| US8969415B2 (en) * | 2006-12-01 | 2015-03-03 | Allergan, Inc. | Intraocular drug delivery systems |
| US9095506B2 (en) * | 2008-11-17 | 2015-08-04 | Allergan, Inc. | Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof |
| US20100247606A1 (en) * | 2009-03-25 | 2010-09-30 | Allergan, Inc. | Intraocular sustained release drug delivery systems and methods for treating ocular conditions |
| US20130071349A1 (en) * | 2010-03-02 | 2013-03-21 | Allergan, Inc. | Biodegradable polymers for lowering intraocular pressure |
| EP2595604B1 (en) | 2010-07-21 | 2016-03-30 | Allergan, Inc. | Method of controlling initial drug release of sirna from sustained-release implants |
| ES2751681T3 (es) * | 2013-03-15 | 2020-04-01 | Allergan Inc | Implante intraocular que contiene prostamida |
| KR102159427B1 (ko) | 2015-04-30 | 2020-09-24 | 알러간, 인코포레이티드 | 지방 감소를 위한 미용적 방법 및 치료적 용도 |
-
2014
- 2014-04-09 AU AU2014250937A patent/AU2014250937A1/en not_active Abandoned
- 2014-04-09 KR KR1020157029970A patent/KR20150141972A/ko not_active Ceased
- 2014-04-09 MX MX2015014320A patent/MX381097B/es unknown
- 2014-04-09 US US14/248,898 patent/US20140308354A1/en not_active Abandoned
- 2014-04-09 CA CA2908731A patent/CA2908731A1/en not_active Abandoned
- 2014-04-09 ES ES14725582T patent/ES2785382T3/es active Active
- 2014-04-09 SG SG10201701938PA patent/SG10201701938PA/en unknown
- 2014-04-09 JP JP2016507645A patent/JP2016520561A/ja active Pending
- 2014-04-09 EP EP14725582.2A patent/EP2983663B1/en active Active
- 2014-04-09 BR BR112015025915A patent/BR112015025915A8/pt active Search and Examination
- 2014-04-09 CN CN201910977574.7A patent/CN110840899A/zh active Pending
- 2014-04-09 EP EP20152147.3A patent/EP3656375A1/en not_active Withdrawn
- 2014-04-09 DK DK14725582.2T patent/DK2983663T3/da active
- 2014-04-09 RU RU2015143859A patent/RU2015143859A/ru not_active Application Discontinuation
- 2014-04-09 WO PCT/US2014/033558 patent/WO2014169075A1/en not_active Ceased
- 2014-04-09 MY MYPI2015002531A patent/MY187802A/en unknown
- 2014-04-09 CN CN201480020790.8A patent/CN105101962A/zh active Pending
- 2014-04-09 SG SG10202109919P patent/SG10202109919PA/en unknown
-
2015
- 2015-09-29 ZA ZA2015/07217A patent/ZA201507217B/en unknown
- 2015-10-09 CL CL2015003023A patent/CL2015003023A1/es unknown
- 2015-10-11 IL IL242006A patent/IL242006B/en active IP Right Grant
-
2016
- 2016-04-21 US US15/134,792 patent/US10682361B2/en active Active
-
2019
- 2019-05-08 AU AU2019203214A patent/AU2019203214B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| MX381097B (es) | 2025-03-12 |
| CN110840899A (zh) | 2020-02-28 |
| MX2015014320A (es) | 2015-12-08 |
| EP3656375A1 (en) | 2020-05-27 |
| AU2019203214A1 (en) | 2019-05-30 |
| MY187802A (en) | 2021-10-26 |
| AU2014250937A1 (en) | 2015-10-22 |
| HK1221406A1 (en) | 2017-06-02 |
| KR20150141972A (ko) | 2015-12-21 |
| ES2785382T3 (es) | 2020-10-06 |
| SG10202109919PA (en) | 2021-10-28 |
| RU2015143859A (ru) | 2017-05-16 |
| CA2908731A1 (en) | 2014-10-16 |
| US10682361B2 (en) | 2020-06-16 |
| DK2983663T3 (da) | 2020-04-20 |
| CN105101962A (zh) | 2015-11-25 |
| US20140308354A1 (en) | 2014-10-16 |
| AU2019203214B2 (en) | 2020-10-29 |
| JP2016520561A (ja) | 2016-07-14 |
| WO2014169075A1 (en) | 2014-10-16 |
| RU2015143859A3 (enExample) | 2018-03-05 |
| IL242006B (en) | 2020-04-30 |
| BR112015025915A2 (pt) | 2017-07-25 |
| BR112015025915A8 (pt) | 2020-01-14 |
| EP2983663A1 (en) | 2016-02-17 |
| EP2983663B1 (en) | 2020-01-22 |
| ZA201507217B (en) | 2017-09-27 |
| NZ712804A (en) | 2021-02-26 |
| SG10201701938PA (en) | 2017-04-27 |
| US20160339039A1 (en) | 2016-11-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2015003270A1 (es) | Composiciones y métodos para el suministro tópico de prostaglandinas a la grasa subcutanea. | |
| CY1123953T1 (el) | Καθυστερημενης απελευθερωσης συνθεσεις λινακλοτιδης | |
| CR20130639A (es) | Sistemas y métodos basados en tomografía de coherencia óptica y presión | |
| BR112014024903A2 (pt) | anticorpos biespecíficos contra tweak humanao e il17 humana e seus usos | |
| UY34332A (es) | Composiciones y métodos para controlar malezas co mprendiendo un polinucleótido y agente de transfe rencia, y que modulan la fitoeno desaturasa?. | |
| UY34327A (es) | ?composiciones y métodos para controlar malezas comprendiendo un polinucleótido y agente de transferencia, y que modulan 4-hidrofenil-piruvato-dioxigenasa?. | |
| ECSP18014922A (es) | Composiciones de insulina de rápida acción | |
| CL2014000759A1 (es) | Composicion para uso en el crecimiento del cerebro y/o desarrollo cognitivo y/o desarrollo psicomotor que comprende al menos un ácido graso poliinsaturado de cadena larga (lc-pufa), al menos un probiótico y una mezcla de oligosacáridos; uso de la composición. | |
| CR20160154A (es) | Ácidos grasos octanoico, nonanoico y decanoico con un adulticida piretroide | |
| MX2016003431A (es) | Metodo para producir alcoholes fragantes. | |
| EP2831726A4 (en) | Dynamic plugin(s) for cloud application(s) | |
| CL2016002531A1 (es) | Composición de ácidos grasos monoinsaturados de cadena larga y métodos para la producción de la misma | |
| BR112015022347A2 (pt) | composição para vacinação, método para produzir uma composição para vacinação e uso de composição | |
| CR20160061A (es) | Formulación estable líquida de etelcalcetide (amg 461) | |
| DOP2013000293A (es) | Composiciones líquidas de limpieza de sal | |
| UY35776A (es) | ?antagonistas de receptor ep3 de prostaglandina?. | |
| TWD187972S (zh) | 泵桿式制動器 | |
| EP2964722A4 (en) | PROCESS FOR PROVIDING QUANTUM POINTS (QD) | |
| CL2015001559A1 (es) | Dispersión solida de un modulador selectivo de los receptores de progesterona | |
| MX2015015148A (es) | Proceso para la preparacion de 4-hidroxi-4-metiltetrahidropiranos 2-sustituidos en una cascada de reactores. | |
| BR112013019924A8 (pt) | Composições para cuidado oral | |
| EP3009429A4 (en) | TYPE R RESVERATROLDIMER, MANUFACTURING METHOD AND USE THEREOF IN REDUCING BLOOD SUGAR | |
| MX381097B (es) | Libración sostenida de bimatoprost, análogos de bimatoprost, prostamidas y prostaglandinas para la reducción de grasas. | |
| CO2017005843A2 (es) | Método para reducir las grasas totales y saturadas en rellenos de productos de confitería | |
| UY35823A (es) | Profármacos de antagonista de nmda |